Last update June 29, 2020
Limited compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Adefovir Dipivoxil in other languages or writings:
Main tradenames from several countries containing Adefovir Dipivoxil in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 59 | % |
Molecular weight | 502 | daltons |
Protein Binding | < 4 | % |
VD | 0.4 | l/Kg |
Tmax | 0.6 - 4 | hours |
T½ | 7 - 11 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Adefovir is a nucleotide reverse transcriptase inhibitor, structurally related to adenine, used for treatment of chronic hepatitis B. Usually a long-term treatment is required.
Oral administration once a day.
Since the last update we have not found any published data on its excretion in breast milk.
Its pharmacokinetic data (not very high molecular weight and low protein binding) makes transfer to milk possible in amounts that could be significant. its use during breastfeding is not recommended (Mahadevan 2006).
There is widespread agreement among medical associations and expert consensus that maternal hepatitis B is not transmitted to the infant through breastmilk and therefore does not contraindicate breastfeeding (Mammas 2017,Visvanathan 2016, Dionne 2016, Fouquet 2016, Sogni 2015).
See below the information of these related products: